WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 314215
CAS#: 400827-46-5 (acetate),
Description: Ceftaroline fosamil, also known as TAK 599 and PPI 0903, is an advanced-generation cephalosporin antibiotic. It is active against methicillin-resistant Staphylococcus aureus (MRSA) and Gram-positive bacteria. It retains the activity of later-generation cephalosporins having broad-spectrum activity against Gram-negative bacteria. It is currently being investigated for community-acquired pneumonia and complicated skin and skin structure infection.
MedKoo Cat#: 314215
Name: Ceftaroline fosamil
CAS#: 400827-46-5 (acetate),
Chemical Formula: C24H25N8O10PS4
Exact Mass: 684.01028
Molecular Weight: 744.72
Elemental Analysis: C, 38.71; H, 3.38; N, 15.05; O, 21.48; P, 4.16; S, 17.22
Ceftaroline fosamil, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Related CAS #: 229016-73-3 (free form) 400827-46-5 (acetate)
Synonym: TAK 599; TAK599; TAK-599; PPI 0903; PP 0903; PPI-0903; T-91825; T 91825; T91825; Ceftaroline fosamil; Teflaro; Zinforo
IUPAC/Chemical Name: 4-(2-(((6R,7R)-2-carboxy-7-((Z)-2-(ethoxyimino)-2-(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)thio)thiazol-4-yl)-1-methylpyridin-1-ium acetate
InChi Key: UGHHNQFYEVOFIV-VRDMTWHKSA-N
InChi Code: InChI=1S/C22H21N8O8PS4.C2H4O2/c1-3-38-26-13(16-25-21(43-28-16)27-39(35,36)37)17(31)24-14-18(32)30-15(20(33)34)12(9-40-19(14)30)42-22-23-11(8-41-22)10-4-6-29(2)7-5-10;1-2(3)4/h4-8,14,19H,3,9H2,1-2H3,(H4-,24,25,27,28,31,33,34,35,36,37);1H3,(H,3,4)/b26-13-;/t14-,19-;/m1./s1
SMILES Code: O=C(O)C(N1[C@@]([H])([C@@H](C1=O)NC(/C(C2=NSC(NP(O)(O)=O)=N2)=N\OCC)=O)SC3)=C3SC4=NC(C5=CC=[N+](C=C5)C)=CS4.O=C([O-])C
The following data is based on the product molecular weight 744.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Yang L, Sunzel M, Xu P, Edeki T, Wilson D, Li J, Li H. Evaluation of the pharmacokinetics and safety of single and multiple ceftaroline fosamil infusions in healthy Chinese and Western subjects. Int J Clin Pharmacol Ther. 2015 Jul 8. [Epub ahead of print] PubMed PMID: 26152131.
2: Shandurenko IN. [New antibiotic in treatment of surgical infection: the first experience]. Khirurgiia (Mosk). 2015;(3):81-3. Russian. PubMed PMID: 26031957.
3: Rashid MU, Rosenborg S, Panagiotidis G, Löfdal KS, Weintraub A, Nord CE. Ecological Effect of Ceftaroline-Avibactam on the Normal Human Intestinal Microbiota. Antimicrob Agents Chemother. 2015 May 18. pii: AAC.00530-15. [Epub ahead of print] PubMed PMID: 25987638.
4: Kaye KS, Udeani G, Cole P, Friedland HD. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. Hosp Pract (1995). 2015 May 8:1-6. [Epub ahead of print] PubMed PMID: 25956849.
5: Kiang TK, Wilby KJ, Ensom MH. A Critical Review on the Clinical Pharmacokinetics, Pharmacodynamics, and Clinical Trials of Ceftaroline. Clin Pharmacokinet. 2015 May 5. [Epub ahead of print] PubMed PMID: 25940827.
6: Maggiore C, Vazquez JA, Guervil DJ, Ramani A, Jandourek A, Cole P, Friedland HD. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit. Ther Clin Risk Manag. 2015 Apr 2;11:557-63. doi: 10.2147/TCRM.S75191. eCollection 2015. PubMed PMID: 25897240; PubMed Central PMCID: PMC4397928.
7: Justo JA, Mayer SM, Pai MP, Soriano MM, Danziger LH, Novak RM, Rodvold KA. Pharmacokinetics of Ceftaroline in Normal Body Weight and Obese (Classes I, II, and III) Healthy Adult Subjects. Antimicrob Agents Chemother. 2015 Jul;59(7):3956-65. doi: 10.1128/AAC.00498-15. Epub 2015 Apr 20. PubMed PMID: 25896707; PubMed Central PMCID: PMC4468711.
8: Guervil DJ, Kaye KS, Hassoun A, Cole P, Huang XY, Friedland HD. Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP). J Chemother. 2015 Mar 30:1973947815Y0000000010. [Epub ahead of print] PubMed PMID: 25817579.
9: Tarral A, Merdjan H. Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. Clin Ther. 2015 Apr 1;37(4):877-86. doi: 10.1016/j.clinthera.2015.01.009. Epub 2015 Mar 10. PubMed PMID: 25769615.
10: Fabre V, Ferrada M, Buckel WR, Avdic E, Cosgrove SE. Ceftaroline in Combination With Trimethoprim-Sulfamethoxazole for Salvage Therapy of Methicillin-Resistant Staphylococcus aureus Bacteremia and Endocarditis. Open Forum Infect Dis. 2014 Jul 8;1(2):ofu046. doi: 10.1093/ofid/ofu046. eCollection 2014 Sep. PubMed PMID: 25734118; PubMed Central PMCID: PMC4281789.
